 |
市場調查報告書
商品編碼
1983266
Budesonide吸入劑市場：依產品類型、劑型、活性成分濃度、通路及地區分類Budesonide Inhaler Market, By Product Type, By Dosage Form, By Strength, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，Budesonide吸入器市場規模將達到 87.09 億美元，到 2033 年將達到 130.99 億美元。預計 2026 年至 2033 年的複合年成長率將達到 6%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 87.09億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 6.00% | 預計金額（2033 年） | 130.99億美元 |
Budesonide是一種人工合成的糖皮質激素，與腎上腺分泌的天然激素皮質醇和Hydrocortisone類似。它用於治療氣喘。Budesonide的商品名為「普米克令舒（Pulmicort）」。依型號不同，每支Budesonide吸入器可提供60至120次吸入。隨著人口的成長，全球氣喘盛行率預計將上升。例如，根據世界衛生組織（WHO）2022年5月11日發布的報告，氣喘是影響所有年齡層（從兒童到成人）的主要非傳染性疾病（NCD），也是全球兒童中最常見的慢性疾病。 2019年，估計有2.62億人患有氣喘，導致全球45.5萬人死亡。許多氣喘相關死亡病例發生在印度和孟加拉等低收入和中低收入國家，這些國家面臨診斷和治療不足的嚴峻挑戰。
市場動態
受氣喘發病率和盛行率上升的推動，預計預測期內全球對Budesonide吸入器的需求將顯著成長。根據2018年全球氣喘報告，氣喘每天造成約1,000人死亡，影響全球3.39億人。
預計在預測期內，主要市場參與者推出新產品的增加將推動全球Budesonide吸入器市場的成長。例如，2019年11月，製藥公司Lupin宣布推出一款設備，用於追蹤慢性呼吸系統疾病患者使用定量吸入器（MDI）的情況。該設備可幫助患者了解其MDI使用情況，並有助於提高治療順從性。吸入器是治療氣喘和慢性阻塞性肺病（COPD）等慢性呼吸系統疾病的一種選擇。
本報告的主要特點
- 本報告指出了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本文根據以下參數，介紹了全球Budesonide吸入器市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
- 《全球Budesonide吸入器市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球Budesonide吸入器市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機遇
- 影響分析
- 市場趨勢
- 主要進展
- 監理情勢
- 產品召回
- 流行病學分析
- 技術概述
- PEST分析
- 波特五力模型
第4章 全球Budesonide吸入器市場：依產品類型分類（2026-2033 年）
- 概述
- 吸入器
- 噴霧器
第5章 全球Budesonide吸入劑市場：依劑型分類（2026-2033 年）
- 概述
- 氣霧劑
- 乾粉
- 懸浮液
- 噴
第6章 全球Budesonide吸入劑市場：依活性成分濃度分類（2026-2033 年）
- 概述
- 25mg
- 5mg
- 0mg
第7章 全球Budesonide吸入器市場：依分銷管道分類（2026-2033 年）
- 概述
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 全球Budesonide吸入器市場：按地區分類（2026-2033 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- 熱圖分析
- 公司簡介
- Pfizer, Inc.
- Cipla Limited
- Lupin Limited
- Cosmo Pharmaceuticals
- Takeda Pharmaceutical Company Ltd
- Manus Aktteva Biopharma LLP
- Abbott Laboratories
- Lunan Better Pharmaceutical
- Novartis International AG（Sandoz）
- Mylan NV
- Skyepharma
- AstraZeneca Plc.
- Chiesi Farmaceutici SpA
- Orion Corporation
- Santarus Inc.
- Synmosa Biopharma Corporation
- Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
第10章
- 參考
- 分析方法
- 關於 Coherent Market Insights
簡介目錄
Product Code: CMI2551
Budesonide Inhaler Market is estimated to be valued at USD 8,709 Mn in 2026 and is expected to reach USD 13,099 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8,709 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.00% | 2033 Value Projection: | USD 13,099 Mn |
Budesonide is an artificial glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone, which is produced in the adrenal glands. It is used for treating asthma. Budesonide is sold under the brand name Pulmicort. Each budesonide inhaler is designed to provide 60 to 120 inhalations depending on the device. Increasing air population is expected to lead to high prevalence of asthma worldwide. For instance, on May 11, 2022, according to the World Health Organization (WHO), Asthma is a major non-communicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children globally. Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths globally. Most asthma-related deaths occur in low- and lower-middle-income countries such as India and Bangladesh, where under-diagnosis and under-treatment is a challenge.
Market Dynamics
The global demand for budesonide inhaler is expected to witness substantial growth over the forecast period, owing to increasing incidences and prevalence of asthma. According to the Global Asthma Report 2018, asthma causes around 1,000 deaths every day and affects as many as 339 million people worldwide.
Increasing product launch by the key market player in expected to boost the growth of global budesonide inhaler market over the forecast period. For instance, in November 2019, Lupin, Pharmaceutical Company, announced the launch of device to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases. The device helped the patients track their metered-dose inhalers (MDI) usage and facilitate improved adherence to therapy. The inhalers are the treatment option for managing chronic respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD).
Key features of the study
- This report provides an in-depth analysis of the global budesonide inhaler market, market size (USD Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 - 2030, considering 2021 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global budesonide inhaler market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global budesonide inhaler market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global budesonide inhaler market.
Budesonide Inhaler Market Segmentation
- By Product Type Insights (Revenue, USD Mn, 2020 - 2033)
- Inhalants
- Nebulizer
- By Dosage Form Insights (Revenue, USD Mn, 2020 - 2033)
- Aerosols
- Dry Powder
- Suspension
- Sprays
- By Strength Insights (Revenue, USD Mn, 2020 - 2033)
- 0.25mg
- 0.5mg
- 1.0mg
- By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Pfizer Inc.
- Cipla Limited
- Lupin Limited
- Cosmo Pharmaceuticals
- Takeda Pharmaceutical Company Ltd.
- Manus Aktteva Biopharma LLP
- Abbott Laboratories
- Lunan Better Pharmaceutical
- Novartis International AG (Sandoz)
- Mylan N.V.
- Skyepharma
- AstraZeneca Plc.
- Chiesi Farmaceutici S.p.A
- Orion Corporation
- Santarus Inc.
- Synmosa Biopharma Corporation
- Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Dosage Form
- Market Snapshot, By Strength
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Landscape
- Product Recall
- Epidemiology Analysis
- Technology Overview
- PEST Analysis
- Porter's Five Forces Model
4. Global Budesonide Inhaler Market, By Product Type, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Inhalants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Nebulizers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
5. Global Budesonide Inhaler Market, By Dosage Form, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Aerosols
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Dry Powder
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Suspension
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Spray
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
6. Global Budesonide Inhaler Market, By Strength, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- 25mg
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- 5mg
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- 0mg
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
7. Global Budesonide Inhaler Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
8. Global Budesonide Inhaler Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Company Profile
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cosmo Pharmaceuticals
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Takeda Pharmaceutical Company Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Manus Aktteva Biopharma LLP
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lunan Better Pharmaceutical
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis International AG (Sandoz)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Skyepharma
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Chiesi Farmaceutici S.p.A.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Orion Corporation
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Santarus Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Synmosa Biopharma Corporation
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
